Chest
Clinical InvestigationsCOPDCharacteristics of Airway Inflammation and Bronchodilator Reversibility in COPD: A Potential Guide to Treatment
Section snippets
Subjects
This was a prospective study to investigate airway inflammation and bronchodilator reversibility in stable patients with smoking-related COPD who used medications regularly. Eighty-eight male patients were recruited from our outpatient clinic. COPD was diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease guidelines1 from observing symptoms of progressive shortness of breath, productive cough, and occasional wheezing. All patients were treated with theophylline, oral
Results
The characteristics of all study subjects are listed in Table 1. The two groups of COPD patients were similar in age and baseline pulmonary function except for bronchodilator reversibility of FEV1 and FVC.
Discussion
The results of this study show that a substantial degree of eosinophilic inflammation can be observed in COPD, although no study subjects had a history of asthma and allergy, and all had received diagnoses that had been determined according to the Global Initiative for Chronic Obstructive Lung Disease guidelines.1 Sputum neutrophils, but not eosinophils, in stable COPD patients were significantly negatively correlated with FEV1 percent predicted. These correlations were more robust in COPD
References (34)
- et al.
Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease
J Allergy Clin Immunol
(1993) - et al.
Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema
Chest
(1999) - et al.
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial
Lancet
(2000) - et al.
Eosinophils in induced sputum from asymptomatic smokers with normal lung function
Respir Med
(2001) - et al.
Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses
Chest
(2003) - et al.
Reversibility to a beta2-agonist in COPD: relationship to atopy and neutrophil activation
Respir Med
(2003) - et al.
Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison with that in normal subjects
Chest
(1989) Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report
(2001)- et al.
Eosinophilic inflammation in asthma
N Engl J Med
(1990) - et al.
Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects
Am Rev Respir Dis
(1993)
Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis
Am Rev Respir Dis
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma
Am J Respir Crit Care Med
Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD
Thorax
Eosinophilic inflammation in stable chronic obstructive pulmonary disease: relationship with neutrophils and airway function
Am J Respir Crit Care Med
The relationship between airways inflammation and asthma severity
Am J Respir Crit Care Med
Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma
Am Rev Respir Dis
Glucocorticoid therapy for chronic obstructive pulmonary disease
N Engl J Med
Cited by (81)
Fractional Exhaled Nitric Oxide Guided-Therapy in Chronic Obstructive Pulmonary Disease: A Stratified, Randomized, Controlled Trial
2022, Archivos de BronconeumologiaPost-bronchodilator Reversibility of FEV<inf>1</inf> and Eosinophilic Airway Inflammation in COPD
2017, Archivos de BronconeumologiaCitation Excerpt :The study was approved by the Institutional Review Board of Taipei Veterans General Hospital (VGHIRB No. 2015-09-004AC) and reported in accordance with the STROBE statement.6 Data from sputum analyses and bronchodilator tests from COPD patients included in our prospective clinical trials from 2002 to 20127–10 were retrospectively collected and analyzed. The process of patient selection is detailed in Fig. A1 in the appendix.
The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD
2015, Pulmonary Pharmacology and TherapeuticsEffects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD
2014, Pulmonary Pharmacology and TherapeuticsAssociation of Absolute Eosinophil Count and Post-Bronchodilator Reversibility in the Chronic Obstructive Pulmonary Disease Patients
2023, Pakistan Armed Forces Medical Journal
This work was supported by research grants from Taipei Veterans General Hospital (VGH93–185). There is no potential conflict of interest involved in this study.